Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions - Poll - MDSpire

Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions

  • By

  • Jiasheng Zhou

  • Bo Liu

  • Qiao Yang

  • Jingxuan Zhou

  • Jiahao Zheng

  • Yujin Chen

  • Lie Fu

  • Jianhui Du

  • Zhegang Zhang

  • Jiayou Zhang

  • Changgui Li

  • July 16, 2026

Share

Original Source(s)

Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions

  • by Jiasheng Zhou, Bo Liu, Qiao Yang, Jingxuan Zhou, Jiahao Zheng, Yujin Chen, Lie Fu, Jianhui Du, Zhegang Zhang, Jiayou Zhang, Changgui Li

  • July 16, 2026

Related Content

Reappraising traumatic brain injury and ventilator-associated pneumonia through the brain-lung-immune-microbiome axis

Does High PCT Warrant Longer Therapy?

In a planned BALANCE analysis, elevated day 7 procalcitonin was associated with higher mortality, but the small subgroup analysis found no evidence that extending antibiotics from 7 to 14 days improved outcomes.

Mucosal and systemic immune signatures reveal compartmentalized regulation of gut barrier integrity in virologically suppressed HIV Infection